See the latest news and media coverage for Bio-Techne. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life sciences company developing reagents, instruments, and analytical services
bio-techne.comLast updated
In short: Bio-Techne agreed to an $11.3 billion acquisition by Merck KGaA and reported stable fiscal 2026 results while celebrating 50 years.
The company highlights improved performance and positions for the planned Merck KGaA acquisition, which is expected to benefit customers and employees. Bio-Techne remains independent until closing.
The company highlights five decades of supporting breakthrough research and enabling next-generation therapies, with plans to expand impact globally after the transaction closes.
The purchase price is $73 per share in cash, with an enterprise value of $11.3 billion, and the deal is expected to close by early 2027.
The workflow combines icIEF fractionation with mass photometry to directly correlate charge and size variants in a four-hour process.
Bio-Techne Corporation (NASDAQ:TECH) on Monday released supplemental disclosures related to its pending merger with Merck KGaA, Darmstadt, Germany, following a shareholder lawsuit and the receipt...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders....
Bio-Techne’s $11.3 billion deal to be acquired by Merck highlights a global surge in mega-deals and leads activity in.
Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.
Track Bio-Techne and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Bio-Techne and other trending companies.